Examples of 'immunostimulatory oligonucleotides' in a sentence
Meaning of "immunostimulatory oligonucleotides"
Immunostimulatory oligonucleotides: Immunostimulatory oligonucleotides (ISS) are short DNA or RNA sequences that can activate the immune system. They are used in immunotherapy to boost the body's immune response against diseases such as cancer or infections
How to use "immunostimulatory oligonucleotides" in a sentence
Basic
Advanced
immunostimulatory oligonucleotides
Immunostimulatory oligonucleotides can be free of CpG dinucleotides.
Novel vaccine compositions comprising immunostimulatory oligonucleotides.
Immunostimulatory oligonucleotides may otherwise be free of CpG dinucleotides.
Different classes of CpG immunostimulatory oligonucleotides have been identified.
Immunostimulatory oligonucleotides with adjuvant activity are well known.
Long term disease modification using immunostimulatory oligonucleotides.
Alternative immunostimulatory oligonucleotides may comprise modifications to the nucleotides.
They are not limited to the formulation of immunostimulatory oligonucleotides.
The CpG immunostimulatory oligonucleotides are also useful as mucosal adjuvants.
In some embodiments the compositions are useful for formulating immunostimulatory oligonucleotides.
In other embodiments the immunostimulatory oligonucleotides are free of CpG dinucleotides.
Semi-soft oligonucleotides generally possess increased immunostimulatory potency relative to corresponding fully stabilized immunostimulatory oligonucleotides.
The immunostimulatory oligonucleotides of the instant invention have a modified backbone.
Example of such new adjuvants include immunostimulatory oligonucleotides like CpG nucleotides.
The immunostimulatory oligonucleotides of the invention may optionally have chimeric backbones.
See also
HBsAg particles can also be used to deliver immunostimulatory oligonucleotides.
In some instances the immunostimulatory oligonucleotides can form intermolecular duplexes.
Therefore the TLR9 ligands of the invention are immunostimulatory oligonucleotides.
Immunostimulatory oligonucleotides were created as immunomers using the following protocols for synthesis.
In one embodiment the duplex forming immunostimulatory oligonucleotides are any of the aforementioned oligonucleotides.
Immunostimulatory oligonucleotides of the invention comprise at least one phosphorothioate modified backbone.
For example, in some embodiments immunostimulatory oligonucleotides can be used.
The immunostimulatory oligonucleotides of the instant invention can be used to treat allergy.
In still another embodiment, the CpG immunostimulatory oligonucleotides are useful for treating cancer.
The immunostimulatory oligonucleotides of the disclosure can also be conjugated to a lipophilic group.
A substantially homogenous mixture of duplex forming immunostimulatory oligonucleotides obtainable by the method of claim 17.
The immunostimulatory oligonucleotides of the invention comprise at least one phosphorothioate backbone modification.
Semi-soft oligonucleotides can have a number of advantages over immunostimulatory oligonucleotides with fully stabilized backbones.
The immunostimulatory oligonucleotides of the invention stimulate cytokine production in a subject for example.
Therefore the TLR9 ligands described herein by way of example are immunostimulatory oligonucleotides.
The immunostimulatory oligonucleotides of the invention thus include at least one immunostimulatory motif.
The cation connects two G-quadruplexes and minimizes the electrostatic interactions between the immunostimulatory oligonucleotides.
In some instances the immunostimulatory oligonucleotides can form both intermolecular and intramolecular duplexes.
A particularly useful adjuvant based around immunostimulatory oligonucleotides is known as IC31 ™.
The CpG immunostimulatory oligonucleotides are also useful for treating and preventing autoimmune diseases.
A particularly useful adjuvant based around immunostimulatory oligonucleotides is known as IC-31 ™ Schellack et al.
The CpG immunostimulatory oligonucleotides are also useful for treating and prevneting autoimmune disease.
A non-limiting set of immunostimulatory oligonucleotides includes,.
The immunostimulatory oligonucleotides of the instant invention can be administered concurrently with a traditional antiviral treatment.
The adjuvant may further comprise immunostimulatory oligonucleotides ( for example, CpG ) or a carrier.
CpG immunostimulatory oligonucleotides are capable of provoking a broad spectrum of immune response.
In yet other embodiments immunostimulatory oligonucleotides have a mixed PO and PS backbone.
CpG immunostimulatory oligonucleotides can be used to enhance the effects of adjuvants in a vaccine setting.
In other instances, the CpG immunostimulatory oligonucleotides may be delivered with low doses of self-antigens.
Immunostimulatory oligonucleotides will typically comprise at least 20 nucleotides.
In a preferred embodiment, the immunostimulatory oligonucleotides of the invention are advantageously modified into stabilized oligonucleotides.
Immunostimulatory oligonucleotides or any other Toll-like receptor ( TIR ) 9 agonist may also be used.
For facilitating uptake into cells immunostimulatory oligonucleotides preferably have a minimum length of 6 nucleotide residues.
The immunostimulatory oligonucleotides include immunostimulatory motifs which are " CpG dinucleotides ".
In other embodiments the immunostimulatory oligonucleotides have a phosphodiester ( PO ) backbone.
You'll also be interested in:
Examples of using Oligonucleotides
Show more
Longer oligonucleotides lead to increased transformation efficiency
Corresponding synthetic miRNA oligonucleotides were used as standards
Two oligonucleotides are constructed from this sequence
Examples of using Immunostimulatory
Show more
This agent may have immunostimulatory effects
Immunostimulatory oligonucleotides can be free of CpG dinucleotides
A muramyl dipeptide derivative is the immunostimulatory component
